Evaxion Biotech A/S ADR (NASDAQ:EVAX)’s traded shares stood at 6.26 million during the last session, with the company’s beta value hitting -0.34. At the close of trading, the stock’s price was $0.85, to imply a decrease of -5.45% or -$0.04 in intraday trading. The EVAX share’s 52-week high remains $13.61, putting it -1501.18% down since that peak but still an impressive 0.0% since price per share fell to its 52-week low of $0.85. The company has a valuation of $4.58M, with an average of 0.13 million shares in intraday trading volume over the past 10 days and average of 61.56K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Evaxion Biotech A/S ADR (EVAX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give EVAX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.03.
Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information
After registering a -5.45% downside in the last session, Evaxion Biotech A/S ADR (EVAX) has traded red over the past five days. The 5-day price performance for the stock is -3.86%, and -43.97% over 30 days. With these gigs, the year-to-date price performance is -87.66%. Short interest in Evaxion Biotech A/S ADR (NASDAQ:EVAX) saw shorts transact 31389.0 shares and set a 0.75 days time to cover.
Evaxion Biotech A/S ADR (EVAX) estimates and forecasts
Looking at statistics comparing Evaxion Biotech A/S ADR share performance against respective industry, we note that the company has outperformed competitors. Evaxion Biotech A/S ADR (EVAX) shares are -70.52% down over the last 6 months, with its year-to-date growth rate higher than industry average at 81.48% against 16.70%.
Revenue forecast for the current quarter as set by 2 analysts is 1.66M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 3.2M.
EVAX Dividends
Evaxion Biotech A/S ADR has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
